Andrade Bruno Silva, Rangel Fernanda de Souza, Santos Naiane Oliveira, Freitas Andria Dos Santos, Soares Wagner Rodrigues de Assis, Siqueira Sérgio, Barh Debmalya, Góes-Neto Aristóteles, Birbrair Alexander, Azevedo Vasco Ariston de Carvalho
Laboratório de Bioinformática e Química Computacional, Departamento de Ciências Biológicas, Universidade Estadual do Sudoeste da Bahia (UESB), Jequié, Brazil.
Programa de Pós-graduação em Genética e Biologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Brazil.
Front Pharmacol. 2020 Dec 14;11:590598. doi: 10.3389/fphar.2020.590598. eCollection 2020.
The SARS-CoV-2 outbreak originally appeared in China in December 2019 and became a global pandemic in March 2020. This infectious disease has directly affected public health and the world economy. Several palliative therapeutic treatments and prophylaxis strategies have been used to control the progress of this viral infection, including pre-(PrEP) and post-exposure prophylaxis. On the other hand, research groups around the world are still studying novel drug prophylaxis and treatment using repurposing approaches, as well as vaccination options, which are in different pre-clinical and clinical testing phases. This systematic review evaluated 1,228 articles from the PubMed and Scopus indexing databases, following the Kitchenham bibliographic searching protocol, with the aim to list drug candidates, potentially approved to be used as new options for SARS-CoV-2 prophylaxis clinical trials and medical protocols. In searching protocol, we used the following keywords: "Covid-19 or SARS-CoV-2" or "Coronavirus or 2019 nCoV," "prophylaxis," "prophylactic," "pre-exposure," "COVID-19 or SARS-CoV-2 Chemoprophylaxis," "repurposed," "strategies," "clinical," "trials," "anti-SARS-CoV-2," "anti-covid-19," "Antiviral," "Therapy prevention ," in cells "and" human testing. After all protocol steps, we selected 60 articles that included: 15 studies with clinical data, 22 studies that used experiments, seven studies using animal models, and 18 studies performed with in silico experiments. Additionally, we included more 22 compounds between FDA approved drugs and drug-like like molecules, which were tested in large-scale screenings, as well as those repurposed approved drugs with new mechanism of actions. The drugs selected in this review can assist clinical studies and medical guidelines on the rational repurposing of known antiviral drugs for COVID-19 prophylaxis.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫情于2019年12月最初在中国出现，并于2020年3月成为全球大流行疾病。这种传染病直接影响了公众健康和世界经济。已经采用了几种姑息性治疗方法和预防策略来控制这种病毒感染的进展，包括暴露前预防（PrEP）和暴露后预防。另一方面，世界各地的研究小组仍在研究使用重新利用方法的新型药物预防和治疗方法，以及处于不同临床前和临床试验阶段的疫苗接种方案。本系统评价按照基奇纳姆文献检索协议，对来自PubMed和Scopus索引数据库的1228篇文章进行了评估，目的是列出可能被批准用作SARS-CoV-2预防临床试验和医疗方案新选择的候选药物。在检索协议中，我们使用了以下关键词：“新冠病毒病或SARS-CoV-2”或“冠状病毒或2019新型冠状病毒”、“预防”、“预防性的”、“暴露前”、“新冠病毒病或SARS-CoV-2化学预防”、“重新利用的”、“策略”、“临床”、“试验”、“抗SARS-CoV-2”、“抗新冠病毒病”、“抗病毒”、“治疗预防”、“在细胞中”以及“人体试验”。在完成所有协议步骤后，我们选择了60篇文章，其中包括：15项有临床数据的研究、22项使用实验的研究、7项使用动物模型的研究以及18项进行计算机模拟实验的研究。此外，我们还纳入了另外22种化合物，这些化合物来自美国食品药品监督管理局（FDA）批准的药物和类药物分子，它们在大规模筛选中进行了测试，以及那些具有新作用机制且重新利用的批准药物。本评价中所选药物可协助关于合理重新利用已知抗病毒药物进行新冠病毒病预防的临床研究和医学指南。
